Objective-Inhibitor of differentiation-3 (Id3) has been implicated in promoting angiogenesis, a key determinant of high-fat diet (HFD)-induced visceral adiposity. Yet the role of Id3 in HFD-induced angiogenesis and visceral adipose expansion is unknown. Methods and Results-Id3 Ϫ/Ϫ mice demonstrated a significant attenuation of HFD-induced visceral fat depot expansion compared to wild type littermate controls. Importantly, unlike other Id proteins, loss of Id3 did not affect adipose depot size in young mice fed chow diet or differentiation of adipocytes in vitro or in vivo. Contrast enhanced ultrasound revealed a significant attenuation of visceral fat microvascular blood volume in HFD-fed mice null for Id3 compared to wild type controls. HFD induced Id3 and VEGFA expression in the visceral stromal vascular fraction and Id3 Ϫ/Ϫ mice had significantly lower levels of VEGFA protein in visceral adipose tissue compared to wild type. Furthermore, HFD-induced VEGFA expression in visceral adipose tissue was completely abolished by loss of Id3. Consistent with this effect, Id3 abolished E12-mediated repression of VEGFA promoter activity. Conclusion-Results identify Id3 as an important regulator of HFD-induced visceral adipose VEGFA expression, microvascular blood volume, and depot expansion. Inhibition of Id3 may have potential as a therapeutic strategy to limit visceral adiposity. (Arterioscler Thromb Vasc Biol. 2012;32:317-324.)
O besity, an important contributor to atherosclerosis and diabetes, [1] [2] [3] is increasing in an epidemic manner. Yet, not all obese individuals are at the same risk of developing these diseases. Individuals with central fat accumulation, or visceral obesity, are at higher risk. 4 -7 As such, understanding the molecular and cellular mechanisms mediating visceral adiposity may have important implications for future therapies to limit morbidity and mortality due to obesity.
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Angiogenesis is tightly linked with adipogenesis. 8 New blood vessel formation contributes to adipose tissue growth by delivering nutrients, growth factors, and progenitor and inflammatory cells. Recent evidence suggests that modulation of adipose tissue angiogenesis may be a novel therapeutic option for treating obesity and preventing obesity-related morbidity. 9 The helix-loop-helix (HLH) factors, Id1 and Id3, regulate tumor angiogenesis, 10 yet their role in adipose angiogenesis and diet-induced obesity are unknown. The inhibitor of differentiation or inhibitor of DNA binding (Id) proteins (Id1, Id2, Id3, and Id4), belong to the family of HLH transcription regulators. Id proteins lack a DNA-binding domain but act as dominant negative inhibitors of gene regulation by associating with the broadly expressed E proteins and preventing them from forming homo-or heterodimers with other bHLH factors and binding DNA. 11 Id proteins are negative regulators of cell differentiation and play key roles in the regulation of lineage commitment, cell fate decisions, and in the timing of differentiation. 12 Ids 1 to 4 are all expressed in cultured preadipocytes 13, 14 and in adult adipose tissue in vivo, 15 yet expression in response to differentiation media or high-fat feeding suggests unique roles for each of the Id proteins in the regulation of adipocyte differentiation and adipose tissue development. [13] [14] [15] Recent studies provide evidence that Id2 and Id4 promote adipocyte differentiation and adipose development. Mice null for Id2 have smaller inguinal and intrascapular adipose depot sizes at 4 days of age, 15 whereas data from Id4 null mice demonstrate smaller epididymal and brown adipose depots than their litter mate controls at birth and on chow diet. 13 Previous studies reveal conflicting data on the impact of Id3 overexpression on adipocyte differentiation of cultured preadipocytes. 14, 16 In vivo studies demonstrate that Apoe Ϫ/Ϫ mice null for Id3 have increased adiponectin protein in visceral adipose tissue and in serum 16 ; however, the effect of Id3 on the development of adiposity is unknown.
The present study is the first to demonstrate that mice null for Id3 have a significant attenuation of high-fat diet (HFD)induced obesity. Furthermore, the effect of loss of Id3 on adiposity was more marked in the visceral depots. Consistent with these findings, Id3 was more abundantly expressed in visceral compared to subcutaneous (SC) fat, and Id3 expression was induced by HFD in visceral but not SC adipose tissue. Mice null for Id3 had no differences in adipocyte differentiation markers or enzymes involved in lipid metabolism when fed either a chow or HFD. Instead, mice null for Id3 had significantly reduced visceral depot VEGFA expression and blood volume compared to C57BL/6 (wild type [WT]) controls. Consistent with the paradigm of Id3 function, the HLH factor E12 significantly repressed VEGFA promoter activation; an effect antagonized by expression of Id3. Collectively, these results provide evidence that, in mice fed a HFD, Id3 promotes VEGFA expression, microvascular blood volume, and depot expansion in visceral adipose tissue, suggesting a potential new target to limit visceral adiposity.
Research Design and Methods

Animals
Id3 Ϫ/Ϫ mice used in these studies were on a pure C57BL/6 background (confirmed by microsatellite testing). Male Id3 Ϫ/Ϫ and C57BL/6 (WT) litter-mate controls were used for all experiments. Epididymal, SC, and retroperitoneal fat depots were harvested for analysis according to the technique of Hausman et al. 17 Details of the materials and methods used for the evaluation of body composition by DEXA, measurement of serum parameters, isolation of adipocytes, quantitative PCR, Western blotting, promoter-reporter assays, and metabolic cage measurements are provided in the Supplemental Data, available online at http://atvb.ahajournals.org.
Statistics
Details are provided in the Supplemental Data.
Results
Id3 Expression is Induced by High Fat Feeding in Visceral But Not in Subcutaneous Fat
C57BL/6 (WT) male mice were fed either a chow diet or HFD containing 60% kcal from fat for 4 weeks starting at 3 to 4 weeks of age. After 4 weeks, there was a significant increase in both visceral ( Figure 1A ) and SC ( Figure 1C ) adipose tissue depots with HFD, although the effect on the visceral depot was more marked. Western blot analysis revealed a clear HFD-induced increase in Id3 protein expression in the visceral, but not SC depots ( Figure 1B and 1D), suggesting a preferential role for Id3 in HFDinduced visceral adiposity. Evaluation of Id3 mRNA and protein levels in the 2 depots from the same animals fed 4 weeks of HFD revealed 2-to 3-fold higher Id3 expression in the visceral depot at both the mRNA and protein levels ( Figure 1E and 1F). To determine if the HFD-induced changes in Id3 expression were due to increased Id3 in the stromal vascular fraction (SVF) or adipocytes, Western blot analysis for Id3 protein was performed on both fractions. Notably, HFD induced a 2-fold increase in Id3 protein in the SVF but had no effect on Id3 expression in isolated visceral adipocytes ( Figure 1G and H).
Mice Null for Id3 Have Reduced Visceral Adiposity in Response to HFD
To evaluate the consequences of loss of Id3 on adiposity in vivo, we fed Id3 Ϫ/Ϫ and WT littermates either chow or HFD. Mice null for Id3 had reduced HFD-induced weight gain ( Figure 2A ) and percent body fat ( Figure 2B ) but no difference in lean body mass ( Figure 2C ) compared to littermate controls. Body length was not different between genotypes. However, Id3 Ϫ/Ϫ mice had a smaller waist circumference compared to controls (Supplemental Figure  IA and IB and representative photo, Figure IC ). In contrast, there were no differences in the weight of Id3 Ϫ/Ϫ mice when compared to their WT littermate controls at baseline or with chow diet feeding ( Figure 2A ). Collectively, these results suggest that Id3 may be important in regulating processes specifically involved in HFD-induced visceral adipose tissue accumulation.
Examination of specific adipose tissue depot weights after 20 weeks of HFD demonstrated significantly smaller visceral (epididymal and retroperitoneal) depot weights in mice null for Id3 ( Figure 2D and 2E). In contrast, although there was a trend to smaller SC depots in Id3 Ϫ/Ϫ mice fed 20 weeks of HFD, there was no significant difference in SC ( Figure 2F ) or brown fat (data not shown) depot weights between genotypes fed chow or HFD.
Id3 ؊/؊ Mice Have Smaller Visceral Adipocytes in Response to HFD Compared to WT Controls
To determine if the decreased visceral fat pad size in mice null for Id3 could be secondary to reduced visceral adipocyte size, we performed H&E staining on the epididymal depots of WT and Id3 Ϫ/Ϫ mice fed HFD for 20 weeks. The adipocytes visualized in the Id3 Ϫ/Ϫ epididymal tissue were smaller than the WT adipocytes and there were more adipocytes counted per high power field ( Figure 3A , B and C). Although previous work has suggested a role for Id3 in adipocyte differentiation in vitro, 14 histological analysis revealed a similar appearance of the adipocytes. Further, Western blot analysis of differentiation markers and quantitative PCR for proteins involved in lipid metabolism confirmed no difference in expression between the visceral adipose tissue of WT and Id3 Ϫ/Ϫ mice (Supplemental Figure II and III). In fact, in vitro analysis of mouse embryonic fibroblasts (MEFs) as well as stromal vascular cells isolated from WT and Id3 Ϫ/Ϫ visceral adipose tissue demonstrated no difference in Oil-red-O staining after differentiation with dexamethasone, 3-isobutyl-1-methylxanthine, and insulin (Supplemental Figure  IV) . Consistent with the findings of smaller visceral adipocytes, Id3 Ϫ/Ϫ mice had significantly lower insulin levels compared to WT controls. Glucose levels measured at the same time and circulating lipid levels were equivalent between the 2 groups (Supplemental Figure V) . Evaluation of metabolic parameters in mice fed 5 weeks of chow showed no difference in food intake, total activity, or oxygen consumption between WT and Id3 null mice (data not shown). In contrast, Id3 null mice fed 5 weeks of HFD had significantly higher average and resting oxygen consumption ( Supplemental Table II ). In addition, Id3Ϫ/Ϫ mice had a trend toward lower serum free fatty acid levels compared to WT controls (1886Ϯ217 versus 2472Ϯ197 mol/L, Pϭ0.076, nϭ5-6 mice per group).
Id3-Dependent Visceral Depot Expansion and Regulation of Microvascular Blood Volume Occurs at Early Time Points
Differences in metabolism of Id3 Ϫ/Ϫ and WT mice fed 5 weeks of HFD and the increase in Id3 expression in visceral adipose tissue after 4 weeks of HFD (Figure 1) suggested that the effect of loss of Id3 on visceral adipose depot size may occur sooner than 20 weeks and be mediated by early responses of the adipose depots to HFD. Indeed, similar to mice fed a HFD for 20 weeks, mice fed 4 weeks of HFD displayed significantly reduced visceral adipose depots: epididymal ( Figure 4A ) and retroperitoneal (data not shown). While, as expected, HFD induced an increase in SC depot weight, there was no difference between genotypes in SC depot weights after HFD. The SC depot was slightly greater in the Id3 Ϫ/Ϫ mice fed chow diet ( Figure 4B ). Together, data suggests that loss of Id3 attenuates the early development of diet-induced obesity through mechanism(s) independent of adipocyte differentiation.
Given the established role of angiogenesis in modulating visceral adiposity and the role of Id3 in regulating tumor angiogenesis, we sought to determine if mice null for Id3 had reduced visceral depot microvasculature by performing contrast enhanced ultrasound of the visceral depot. Contrast enhanced ultrasound has been shown to be an efficient and accurate noninvasive imaging modality to assess angiogenesis in mice. 18 Results demonstrated that compared to WT, Id3 Ϫ/Ϫ mice fed 4 weeks of HFD had significantly lower visceral adipose tissue microbubble accumulation, a measure of microvascular blood volume as an index of microvascular density ( Figure 4C , representative picture with quantitation). Consistent with a role for Id3 in regulating microvascular density, coimmunostaining of visceral adipose tissue from WT mice fed HFD with anti-CD31 and anti-Id3 antibodies revealed CD-31 positive vessels coexpressing Id3 (Supplemental Figure  VI) .
Id3 ؊/؊ Mice Have Reduced Expression of VEGFA in Visceral Fat
To determine a potential mechanism whereby Id3 may regulate angiogenesis in visceral adipose tissue, we evaluated the expression of the potent angiogenic factor, VEGFA, in visceral adipose tissue of WT and Id3 Ϫ/Ϫ mice. Results demonstrated that chow-fed mice null for Id3 had significantly less VEGFA protein expressed in visceral adipose tissue ( Figure 5A ). HFD significantly induced VEGFA expression in visceral adipose tissue of WT but not of Id3 Ϫ/ Ϫmice. In contrast, VEGFA expression was much lower in SC adipose tissue and was not affected by loss of Id3, even in mice challenged with a HFD ( Figure 5B ). Consistent with these data suggesting a visceral depot specific effect of Id3 on HFD-induced VEGFA expression, VEGFA ELISAs confirmed lower local VEGFA protein concentration in visceral adipose tissue from HFD fed Id3 Ϫ/Ϫ mice compared to WT controls. This was not due to a global effect of loss of Id3 in the whole animal on VEGFA expression as there were no differences in circulating VEGFA levels between genotypes ( Figure 5C ). Furthermore, consistent with increased Id3 expression in the SVF in response to HFD, VEGFA is also increased in the SVF after HFD ( Figure 5D ).
The VEGFA promoter contains several E-boxes, CANNTG consensus binding sites for bHLH factors. 19 To more fully elucidate the molecular mechanism whereby Id3 may promote VEGFA expression, we transiently cotrans- fected a 5.2-kb VEGFA promoter-luciferase reporter construct ( Figure 6A ) with expression plasmids encoding Id3 and the Id3-binding partner E12 into NIH 3T3 cells. Results demonstrated a significant repression of VEGFA promoter activation by cotransfected E12; an effect significantly antagonized by cotransfection of increasing amounts of Id3 ( Figure 6B ).
Discussion
Many genes that regulate embryonic development are reexpressed in the adult animal in disease states, such as cancer and cardiovascular disease. 20 -22 These genes make particularly appealing targets of therapy, as they are generally not expressed in normal adult tissues where modulation of expression could lead to untoward effects. Id3 is expressed early in embryonic development, with expression declining as the embryo matures. 23, 24 Previous studies have implicated Id3 in cancer and cardiovascular disease 10, 25 ; however, the present study provides the first evidence implicating Id3 in visceral adipose depot expansion in response to HFD. Although loss of Id3 did not alter visceral depot sizes at baseline, it did result in a significant attenuation of HFD and age-induced visceral depot expansion. This suggests that Id3, independent of its developmental role, functions in the adult animal to modulate the response to HFD leading to visceral adiposity.
Decreased visceral adiposity of Id3 null mice on HFD was associated with lower serum insulin levels and higher metabolic rates. This is consistent with published reports demonstrating an inverse relationship between visceral adipose tissue mass and whole body insulin sensitivity and metabolic rates. [1] [2] [3] [4] [5] [6] In Id3 null mice, the smaller visceral adipose tissue depots contain smaller adipocytes, which have been associated with reduced basal lipolysis. 26 Consistent with decreased adipocyte lipolysis, Id3 null mice showed a trend toward lower free fatty acid levels under HFD conditions. Note that less fat storage in adipose tissue in Id3 null mice does not lead to increased circulating lipid levels and, as indicated by improved insulin sensitivity, increased lipid deposition in other tissues like liver and skeletal muscle. Instead, free fatty acid s may be burned at an increased rate to cover increased energy expenditure. These observations are consistent with a hypothesis that Id3 regulates adipose angiogenesis and consequently adipose tissue expansion and whole body metabolism. Indeed, when angiogenesis was inhibited pharmacolog- ically in mouse models of obesity, smaller adipose tissue mass, improved whole body metabolism, and increased use of fatty acids as energy substrates were observed. 27 However, we cannot rule out the possibility that the metabolic phenotype of our Id3 null mice is due to changes in other tissues that play roles in the regulation of insulin sensitivity and energy homeostasis such as skeletal muscle, liver, and brain. The answer to this question will need to await the availability of mice with cell type-specific deletion of Id3.
In addition to a unique role in visceral versus SC adipose tissue, our data also demonstrate a unique role for Id3 in adipose tissue biology relative to other Id proteins. Both Id2 and Id4 have been implicated in promoting differentiation of adipocytes in vivo and in vitro. 13, 15 Overexpression of Id2 increased expression of PPAR␥, aP2, C/EBPa, and adiponectin and promoted lipid accumulation in 3T3-L1 preadipocytes in response to an adipocyte differentiation cocktail. Conversely, compared to WT, MEFs null for Id2 had decreased expression of PPAR␥, aP2, and adiponectin when treated with adipocyte differentiation media. Moreover, Id2 Ϫ/Ϫ mice had decreased intrascapular and inguinal adipose tissue weights at birth. 15 Similarly, mice lacking Id4 had decreased fat mass compared to control mice even on chow diet, and MEFs null for Id4 had decreased levels of similar markers of adipocyte differentiation. 13 The role of Id3 in adipocyte differentiation has been less clear. Moldes et al demonstrated that Id1, Id2, and Id3 mRNA levels, abundant in multiplying 3T3-F422A cells, drop significantly when the cells are induced to differentiate. Coupled with data demonstrating that overexpression of Id3 resulted in decreased glycerophosphate dehydrogenase activity, a marker of adipocyte differentiation, the authors concluded that Id3 prevented differentiation of preadipose cells. 14 In contrast, our laboratory recently demonstrated that overexpression of Id3 did not alter the expression of the adipocyte differentiation marker, GLUT4, in OP9 or 3T3-L1 cell lines treated with 6 and 10 days of adipocyte differentiation medium respectively, 16 although the effect of Id3 on growth or the differentiated Figure 5 . Epididymal fat pads from Id3 Ϫ/Ϫ mice have less VEGFA protein expression compared to wild type (WT) controls. Four week old male Id3 Ϫ/Ϫ and C57BL/6 (WT) littermates were fed either chow or a high-fat diet (HFD) for 4 weeks. A, Western blot of VEGFA protein expression in visceral fat from WT and Id3 Ϫ/Ϫ mice. B, Quantitative histogram of Western blots from visceral and subcutaneous adipose from WT and Id3 Ϫ/Ϫ mice (nϭ2-3 for each group). VEGFA is expressed as fold increase over WT chow fed and normalized to tubulin. C, ELISA measurements for VEGFA concentration in serum and epididymal adipose tissue lysates from Id3 Ϫ/Ϫ and WT control mice fed HFD for 4 or 7 weeks (nϭ5-6 mice for each genotype were assayed in duplicate). D, Quantitative histogram of Western blots of visceral stromal vascular fraction (SVF) from WT mice fed Chow or HFD for 4 weeks. VEGFA levels are expressed as fold increase over chow fed mice and normalized to tubulin. Representative Western blot results are provided in the inset. phenotype as measured by Oil-red-O staining of these cells was not examined. The present study demonstrated no difference in Oil-red-O staining of WT and Id3 Ϫ/Ϫ MEFs or adipose SVF cells treated with differentiation media. Instead, the present study provides the first in vivo data linking Id3 with adipose tissue development and vascularization in response to HFD. Although both the visceral depot and adipocyte size were smaller in the Id3 Ϫ/Ϫ mice compared to WT controls, there was no difference in the appearance of the mature adipocytes and Western blot analysis of adipose tissue from WT and Id3 Ϫ/Ϫ mice revealed no differences in aP2, PEPCK, or CEBP-␣ protein levels. In addition, there were no differences in mRNA expression of adipocyte differentiation markers between WT and Id3 Ϫ/Ϫ visceral adipocytes (data not shown). Results provide evidence that, in contrast to Id2 and Id4, loss of Id3 does not affect adipocyte differentiation or adipose depot size at baseline but rather attenuates visceral adipose depot expansion in response to HFD.
Our results, demonstrating no differences in adipocyte differentiation markers or proteins involved in lipid metabolism in adipose tissue from WT compared to Id3 null mice, led us to investigate alternate reasons for decreased visceral adiposity in the Id3 null mice. Angiogenesis is necessary for adipose tissue expansion and studies have shown that inhibition of angiogenesis inhibits that growth. 27 It has also been proposed that visceral fat secretes proangiogenic factors, suggesting visceral fat is better adapted for rapid expansion. 28 In addition to promoting adipocyte hypertrophy, adipose tissue angiogenesis allows for inflammatory cell infiltra-tion. 29 Increased levels of lymphocytes are visible in murine visceral adipose tissue after just 3 weeks of high-fat feeding. 30 Continued high-fat feeding leads to enhanced CD8 ϩ T cell infiltration 31 and promotes a CD4 ϩ T H 1 bias, 32 both of which help recruit M1 macrophages to visceral adipose tissue-a key event in the development of insulin resistance. 3, 33 Macrophages 34 and mast cells 35 have also been shown to further enhance adipose tissue angiogenesis in the context of dietinduced obesity, suggesting a positive feedback loop that contributes to the systemic metabolic abnormalities observed in obese individuals. Id proteins have been established as necessary for tumor angiogenesis. Data from this study demonstrates not only that mice null for Id3 have less microvascular blood volume in their epididymal fat depots but also that Id3 regulates visceral adipose tissue VEGFA expression at the protein and promoter level. VEGFA has been implicated as an important mediator of angiogenesis, 36 -38 and serum VEGFA levels are significantly increased in obese compared to lean humans and mice. 39 Taken together, results suggest that loss of Id3 attenuates visceral fat expansion by inhibiting HFD-induced visceral fat VEGFA expression and increased capillary density. Future studies using postmortem histology and other techniques to assess visceral adipose tissue angiogenesis are needed to confirm and extend these findings. Nonetheless, as inhibition of Id3 has been proposed as a strategy to limit angiogenesis in vivo 40 and inhibition of adipose angiogenesis is a current target to attenuate obesity, 9 results hold promise to lead to novel approaches to limit visceral adiposity. 
